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AbstrAct
Introduction A phase of arthralgia may precede the 
emergence of rheumatoid arthritis (RA). Although several 
studies have focused on biomarkers, the relevance of this 
phase for patients is less studied. It is unknown if patients 
already have functional limitations and if this is correlated 
to the extent of subclinical inflammation. Therefore, we 
assessed functional disability in patients with clinically 
suspect arthralgia (CSA), its association with MRI-detected 
subclinical inflammation and its course during progression 
to clinical arthritis.
Methods From April 2012 to March 2015, 241 
patients had arthralgia for <1 year and were, based 
on clinical presentation, considered at risk for RA by 
their rheumatologists. At baseline, Health Assessment 
Questionnaire (HAQ) scores were determined and 
unilateral 1.5 T MRI of metacarpophalangeal, wrist and 
metatarsophalangeal joints were made. Presence of 
MRI-detected subclinical inflammation was assessed 
by summing synovitis, tenosynovitis and bone marrow 
oedema scores (range 0–189). Patients were followed on 
arthritis development and HAQ scores were repeated when 
clinical arthritis had developed.
Results The median HAQ score at presentation with 
CSA was 0.50. Higher MRI-inflammation scores were 
associated with higher HAQ scores (β=0.017, 95% 
CI=0.004 to 0.030). During median 103 weeks follow-up, 
44 patients progressed to clinical arthritis. HAQ scores 
≥1.0 were associated with arthritis development (HR=2.50, 
95% CI=1.03 to 6.10). Within converters, median HAQ 
scores did not increase from presentation with CSA to 
arthritis development (0.88 and 0.75, p=0.36).
Conclusions HAQ scores ≥1.0 at presentation were 
associated with the development of clinical arthritis. 
Functional limitations in the prearthritis phase of CSA were 
as serious as in the early clinical phase, demonstrating the 
relevance of CSA from patients’ perspectives.
IntroductIon
Within rheumatoid arthritis (RA), a symptom-
atic phase may precede the development of 
clinical arthritis.1 A broad range of symptoms 
and signs has been described in this phase.2 
In addition, it has been established that pres-
ence of autoantibodies,3 4 increased levels 
of acute phase reactants5 and MRI-detected 
subclinical inflammation6 are associated with 
progression to clinical arthritis. Although 
several biomarkers have been studied, it is 
still unknown to what extent patients with 
arthralgia at risk for RA experience functional 
disability. In addition, it is undetermined if 
functional disability in this disease stage is 
associated with subclinical inflammation and 
if the functional disability increases during 
progression to clinical arthritis.
The Health Assessment Questionnaire 
(HAQ) is a commonly used instrument to 
measure self-reported functional disability 
in patient groups.7 From the general popu-
lation, it is known that HAQ scores increase 
with age8 and are higher for women.9 The 
median HAQ score for patients presenting 
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What is already known about this subject?
Within rheumatoid arthritis, a symptomatic phase may 
precede the development of clinical arthritis with a 
broad range of symptoms and signs.
What does this study add?
Functional disabilities exist already in the symptomatic 
prearthritis phase, with (on group level) a similar 
severity as when presenting with clinical arthritis.
How might this impact on clinical practice?
Although occurrence of clinically detectable arthritis is 
a major event from the rheumatologist’s perspective 
(as this is mostly the moment of initiation of disease-
modifying antirheumatic drug therapy), it is of less 
importance for patients from a functional perspective.
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with RA is generally 1.0.9 10 It has been demonstrated that 
MRI-detected inflammation in RA was associated with 
increased functional impairment at 6 years follow-up.11
In order to increase the comprehension of patients’ 
experiences on physical functioning in a symptomatic 
prearthritis stage, this study evaluated patients without 
clinical arthritis but with arthralgia that were considered at 
risk for progression to RA by their rheumatologists (clini-
cally suspect arthralgia (CSA)). This study assessed 1) the 
level of functional disability measured with HAQ scores 
in CSA, 2) the association of functional disability with the 
severity of MRI-detected subclinical inflammation, 3) the 
association of functional disability with progression to 
clinical arthritis and 4) the course of HAQ scores during 
progression from CSA to clinical arthritis.
Methods
Patients
Two hundred and forty-one patients were consecutively 
included between April 2012 and March 2015 in the 
Leiden CSA cohort. Patients with CSA had recent-onset 
(<1 year) arthralgia of hand or feet joints and were consid-
ered at risk for RA based on the clinical expertise of the 
rheumatologists.6 Per definition CSA was not present if 
patients presented with clinical arthritis or if another 
explanation for the symptoms (eg, osteoarthritis or fibro-
myalgia) was more likely than imminent RA. Hence, as 
described previously,6 inclusion was mainly based on clin-
ical expertise and patients with evident other diagnoses 
were not studied. Furthermore, laboratory results were 
largely unknown at first visit as general practitioners were 
discouraged to perform additional tests, hence inclusion 
in the cohort was largely based on the findings obtained 
at history taking and physical examination. At baseline, 
questionnaires were completed, among which were HAQ 
and Visual Analogue Scale (VAS, range 0–10) for pain. 
Within 2 weeks after inclusion, an MRI was performed. 
The design of the cohort is further described in refer-
ence 6. Baseline HAQ scores were missing in 37 patients 
(15.4%). No differences were found in baseline char-
acteristics for the patients with known and unknown 
HAQ scores (see online supplementary file 2).
health Assessment Questionnaire
The HAQ-Disability Index (HAQ-DI) was used.12 The 
HAQ is a well-validated questionnaire,13 which comprises 
20 questions, covering 8 categories: dressing and 
grooming, arising, eating, walking, hygiene, reach, grip 
and activities of daily living. Scores for each category 
consist of a scale, ranging 0–3, with 0 being no disability 
and 3 representing full disability. When patients require 
extra devices for certain HAQ activities, like a raised 
toilet or crutches, a lower score for that specific question 
is increased to 2. When a question was already scored 
with a 2 or 3 that score remains unchanged. Each cate-
gory contains at least two questions. The scoring system is 
based on the highest abnormal response in each category. 
The total HAQ score consists of an average of the eight 
categories ranging from 0 to 3 as well, with 3 indicating 
complete disability.
subclinical inflammation detected by MrI
Unilateral contrast-enhanced MRIs were made of the 
second to fifth metacarpophalangeal (MCP), wrist and 
first to fifth metatarsophalangeal  joints of the most 
painful side, or the dominant side in case of equally severe 
symptoms at both sides. Patients were instructed not to 
use non-steroidal anti-inflammatory drugs (NSAIDs) 
24 hours prior to MRI as it has been suggested that NSAIDs 
can lower the extent of MRI-detected synovitis.14 15 An 
MSK-extremity 1.5 T MRI scanner was used. The detailed 
MR protocol is provided in online supplementary file 1. 
In short, before contrast-enhancement a T1-weighted 
sequence was acquired of MCP and wrist joints in the 
coronal plane. Postcontrast, T1-weighted, fat saturated 
sequences were acquired in coronal and axial planes. 
The foot was scanned with two protocols. In the first 
78 patients, a T1-weighted sequence and a T2-weighted 
fat saturated sequence were acquired in the axial plane 
(relative to the anatomical position), before contrast 
agent administration. In the remaining 163 patients, 
postcontrast, T1-weighted, fat saturated sequences were 
acquired in axial and coronal planes. This provided 
more information while reducing scanning times. MRIs 
were scored for bone marrow oedema (BME) and syno-
vitis as defined by the OMERACT Rheumatoid Arthritis 
MRI Scoring system.16 Tenosynovitis was scored as 
described by Haavardsholm et al (also applied at flexor 
and extensor tendons of second to fifth MCP joints).17 
The sum of scores for synovitis, tenosynovitis and BME 
yielded the total MRI-inflammation score; the total score 
ranged between 0 and 189. Scoring was performed by 
two independent trained readers (HWvS, LM) blinded 
to clinical data. Within-reader intraclass correlation coef-
ficients for the total MRI-inflammation score were 0.98 
and 0.99; between-reader interclass correlation coeffi-
cient was 0.96. Mean scores of the two readers were used 
in analyses.
Follow-up
Scheduled follow-up visits were performed at 4, 12 
and 24 months. Additional visits took place at indica-
tion; either if preferred by the patient (because of an 
increase in symptoms) or if felt necessary by the rheu-
matologist). The patients included in this study were all 
followed for development of clinically apparent arthritis 
for ≥1 year. Medical files were studied for established 
arthritis until 22 April 2016. Patients were not treated 
with disease-modifying anti-rheumatic drug (DMARDs) 
(including steroids) in the phase of CSA; NSAIDs were 
allowed. Time to clinical arthritis was defined as time 
from inclusion in the cohort to the date of first detection 
of clinical arthritis. Patients who did not develop arthritis 
were censored at the date that all medical files were 
studied on arthritis development or at the last follow-up 
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Table 1 Patient characteristics at baseline presentation 
with CSA
Patient characteristic n=241
Age in years, mean (SD) 44.3 (12.9)
Female sex, n (%) 187 (77.6)
Family history of RA, n (%) 71 (29.5)
Symptom duration in weeks, median 
(IQR)
18.4 (9.7–48.2)
Presence of morning stiffness ≥60 min * 
†, n (%)
80 (33.2)
BMI in kg/m2, median (IQR) 26.1 (23.6–29.9)
68-TJC, median * (IQR) 6 (3–10)
Current smoker, n (%) 54 (22.4)
Autoantibody status
  ACPA-positive (>7 U/mL), n (%) 32 (13.3)
  IgM-RF-positive (>3.5 IU/mL), n (%) 51 (21.2)
Increased CRP (>10 mg/L), n (%) 53 (22.0)
Daily use of NSAIDs, n (%) 57 (23.6)
Positive for EULAR definition for 
arthralgia suspicious  
for progression to RA,18 n (%)
178 (74)
Baseline VAS pain score, median (IQR) 5 (3–7)
Baseline HAQ score *
First quartile (n=44) <0.25
Second quartile (n=62) 0.25–0.50
Third quartile (n=51) 0.63–0.88
Fourth quartile (n=47) ≥1.0
Symptoms were noted by rheumatologists as reported by the 
patients.
*Missing data were as follows: morning stiffness (27), 68-TJC (4), 
HAQ score (37).
†The presence of symptoms refers to the presence of symptoms 
at the baseline visit.
ACPA, anticitrullinated peptide antibody; BMI, body mass 
index; CRP, C reactive protein; ESR, erythrocyte sedimentation 
rate; EULAR, European League Against Rheumatism; HAQ, 
Health Assessment Questionnaire; NSAIDs, non-steroidal anti-
inflammatory drugs; RF, rheumatoid factor; RA, rheumatoid 
arthritis; TJC, tender joint count; VAS, Visual Analogue Scale.
visit. If patients developed clinical arthritis, the HAQ was 
repeated at that visit. DMARDs (steroids, conventional 
synthetic DMARDs) were only initiated after the identifi-
cation of clinical arthritis. DMARDs were initiated either 
directly at the visit when clinical arthritis was identified or 
at subsequent visits.
sensitivity analyses
Recently, a European League Against Rheumatism 
(EULAR) definition for arthralgia suspicious for 
progression to RA was developed.18 Patients fulfilled 
this definition (with a high sensitivity), if three out of 
seven items were present. The associations between HAQ 
and subclinical inflammation at baseline and between 
HAQ and the development of clinical arthritis were also 
studied in the subgroup of patients that also fulfilled the 
EULAR definition.
statistical analyses
Univariable linear regression models were used 
to investigate the association between subclinical 
MRI inflammation and HAQ scores; models were 
adjusted for age at inclusion. Univariable Cox propor-
tional hazards regression analyses were used to calculate 
HRs for HAQ scores in relation to arthritis development. 
Patients were appointed into quartiles according to their 
total HAQ score to create four subgroups with equal 
numbers. Cox regression was repeated with development 
of RA according to the 2010 classification criteria19 as 
outcome. In multivariable Cox regression, the analysis 
was adjusted for age, gender, presence of MRI-subclin-
ical inflammation and anticitrullinated peptide antibody 
(ACPA) status. A paired t-test was performed to compare 
HAQ and VAS scores for pain at presentation with 
CSA and after conversion to clinical arthritis; patients 
who completed the HAQ or VAS score ≥1 week after 
DMARD prescription were excluded from these analyses. 




Baseline characteristics of the 241 patients included are 
shown in table 1. The mean age was 44.3 years, 78% 
were female. The median HAQ score of the total group 
of patients at baseline was 0.50 (IQR: 0.25–0.88). Thir-
ty-three patients reported the use of extra devices for 
certain HAQ activities, mostly for the categories arising, 
walking and grip.
hAQ score and MrI-detected subclinical inflammation at 
presentation
The association between severity of MRI-detected 
subclinical inflammation and functional disability was 
corrected for age. Patients with CSA who presented 
with higher total MRI-inflammation scores had higher 
HAQ scores (β=0.017, 95% CI=0.004 to 0.030, p=0.010); 
β indicates the per point increase in MRI-inflammation 
score, the HAQ score increased with 0.017 (for inter-
pretation the MRI-inflammation score ranges between 
0 and 189). The synovitis, tenosynovitis and bone 
marrow oedema scores were also studied separately. 
Of the individual types of inflammation, the tenosy-
novitis score showed the strongest association with 
functional disability (β=0.046, 95% CI=0.017 to 0.076) 
vs β=0.024, 95% CI=−0.008 to 0.057) and β=0.026 
(95% CI=−0.004 to 0.057) for synovitis and bone marrow 
oedema , respectively.
hAQ scores at presentation and progression to clinical 
arthritis
During a median follow-up period of 103 weeks, 44 
patients progressed to clinical arthritis. The patients who 
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Figure 1 Kaplan-Meier One Minus Survival plot showing cumulative progression to clinical arthritis for patients with clinically 
suspect arthralgia divided in four groups based on their baseline Health Assessment Questionnaire (HAQ) score. Patients 
were appointed into quartiles according to their total HAQ score to create four subgroups with equal numbers (see online 
supplementary file 3). Each line represents one HAQ score quartile and cumulative progression to clinical arthritis. The lowest 
quartile contains patients with HAQ scores <0.25 with n=44 as the reference group. The second quartile contains HAQ scores 
0.25–0.50 (n=62), with an HR for progression to clinical arthritis of 0.67 (95% CI=0.24 to 1.9). Patients in the third quartile had 
HAQ scores 0.63–0.88 (n=51), with an HR for progression to clinical arthritis of 1.3 (95% CI 0.49 to 3.4). Finally, the quartile 
with the highest HAQ scores contains HAQ scores ≥1.0 (n=47). The HR for this quartile (HR=2.50, 95% CI=1.03 to 6.10) was 
significantly elevated compared with the lowest quartile. 
progressed presented with higher baseline HAQ scores 
than patients with CSA who did not progress (median 
0.88 vs 0.50). Four subgroups with equal numbers were 
created to study the association between HAQ scores and 
progression to clinical arthritis in more detail (the quar-
tiles contained four groups with HAQ scores of <0.25, 
0.25–0.50, 0.63–0.88 and ≥1.0, see online supplementary 
file 3). Patients with HAQ scores ≥1.0 had a signifi-
cantly increased hazard on developing clinical arthritis 
(HR=2.50, 95% CI=1.03 to 6.10), compared with the 
patients with HAQ scores <0.25 (figure 1).
Multivariable Cox regression was performed to inves-
tigate the association between HAQ scores and arthritis 
development, adjusting for age, gender, ACPA status 
and presence of MRI-detected subclinical inflammation. 
Higher HAQ scores remained significantly associated 
with arthritis development with HAQ scores <0.25 
as reference: HR 2.6 (95% CI=1.05 to 6.6) for HAQ 
scores ≥1.0. The presence of a positive ACPA test and 
the presence of MRI-detected subclinical inflammation 
were also significantly associated with arthritis devel-
opment in this model (HR=6.7, 95% CI=3.4 to 13.8 
and HR=3.3, 95% CI=1.4 to 8.0, respectively). 
No significant associations were observed for age 
(HR=0.98, 95% CI=0.95 to 1.01) or gender (HR=0.88, 
95% CI=0.40 to 2.0).
At the time that clinical arthritis was identified, 27 of 
the 44 patients with clinical arthritis also fulfilled the 
2010 criteria for RA at that visit.19 Online supplemen-
tary file 4 provides the results of subanalyses with RA as 
outcome. Similar findings were obtained with the highest 
HR for the group of patients with a HAQ >1.0 (HR 2.7, 
95% CI 0.85 to 8.5).
sensitivity analyses in patients fulfilling the eulAr 
definition of arthralgia suspicious for progression to rA
Out of 241 pateints, 178 who were identified as CSA 
by their rheumatologists also fulfilled the EULAR defi-
nition of arthralgia suspicious for progression to RA. 
Also in this subgroup the total MRI inflammation 
scores were associated with the HAQ scores (β=0.015, 
95% CI=0.001 to 0.029, p=0.047) and also here a HAQ 
scores ≥1 were associated with progression to clinical 
arthritis; HR 2.9 (95% CI 1.2 to 7.2).
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Figure 2 Column bar graphs showing Health Assessment Questionnaire (HAQ) scores and pain score on Visual Analogue 
Scale (VAS) (scale 0–10) that were collected at presentation with clinically suspect arthralgia (CSA) and after progression to 
clinical arthritis but before disease-modifying antirheumatic drug (DMARD) initiation. Column bar graphs showing HAQ scores 
and pain score on VAS (scale 0–10) of 25 patients that were serially collected at presentation with CSA (left bar) and after 
progression to clinical arthritis but before DMARD initiation (right bar). A paired t-test for comparisons of median HAQ scores 
and pain scores on VAS (scale 0–10) at both time points (CSA baseline inclusion and the moment of established arthritis) 
revealed no differences (p=0.36 and p=0.11, respectively). 
hAQ and VAs for pain at presentation with csA and at 
arthritis development
HAQ scores at clinical presentation with CSA and after 
arthritis development (and <7 days of DMARD prescrip-
tion) were available in 25 patients. On group level, median 
HAQ scores did not differ between the time of presenta-
tion with CSA and the time of presentation with clinically 
apparent arthritis: median 0.88 (IQR 0.38–1.2) vs 0.75 
(IQR 0.38–1.3), respectively, p=0.36 (figure 2). Intra-
individual changes in HAQ scores over time are shown 
in online supplementary file 5. When the analysis was 
repeated within the patients who completed the HAQ at 
the day, they received a prescription for DMARDs (n=19), 
also no difference in HAQ was observed: median 1.1 
(IQR 0.45–1.2) when presenting with arthralgia and 0.75 
(IQR 0.5–1.3) at clinical arthritis (p value=0.59). Further-
more, also in the subgroup of patients that fulfilled the 
2010 criteria for RA (n=21), the median HAQ did not 
increase between presentation with CSA and clinical 
arthritis development (0.82 and 0.75, p=0.47).
The progression from CSA to clinical arthritis is based 
on an increase in local joint inflammation. As functional 
limitations may associate with inflammation and be a 
direct consequence of pain, we also explored the overall 
level of pain (measured on a VAS ranging 0–10) in CSA 
and at conversion to clinical arthritis. The VAS score 
for pain showed a non-significant tendency towards an 
increase between the phase of CSA and that of early clin-
ical arthritis (median 6.0 and 7.0, respectively, p=0.11, 
figure 2). Thus , despite an increase in inflammation and 
pain, functional disability was already maximal in the 
phase of CSA.
dIscussIon
This longitudinal study showed that patients who develop 
clinical arthritis already have functional limitations in 
the phase of arthralgia. HAQ scores at group level were 
similar at the time of presenting with CSA and after 
emergence of clinical arthritis. Furthermore, severity of 
MRI-detected subclinical inflammation is associated with 
the severity of functional impairments. Together, these 
data demonstrate the functional relevance of the HAQ 
and MRI-detected subclinical inflammation in symptom-
atic patients in the prearthritis stage. This suggests that, 
although occurrence of clinically detectable arthritis is a 
major event from the rheumatologist’s perspective (as this 
is mostly the moment of initiation of DMARD therapy), 
it is of less importance for patients from a functional 
perspective.
Patients with CSA with HAQ scores ≥1.0 in particular 
were at increased risk of progression to clinical arthritis. 
Interestingly, previous studies in early RA cohorts have 
shown that mean HAQ scores at presentation were 1.0.9 10 
This suggests that functional impairments in the symp-
tomatic prearthritis and early clinical phases are of similar 
severity. A previous study comparing patients diagnosed 
with early RA and patients with arthralgia showed similar 
burden of disease among the two groups.20 The presump-
tion of similar burden of disease during the pre-RA phase 
and early RA is further supported by our findings that 
the patients with CSA who progressed to clinical arthritis 
did not experience an increase in functional disability; in 
other words, the maximal level of disability was already 
present when presenting with CSA.
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Patients who presented with CSA but did not progress 
to clinical arthritis presumably also had more func-
tional impairments than the general population, as their 
median HAQ was 0.50 and mean HAQ score of an age-re-
lated normal population (women aged 40–44 years) is 
approximately 0.08.8
We observed that a HAQ ≥1.0 was associated with 
progression to clinical arthritis, independent of other 
predictors (age, gender, ACPA, MRI-detected inflam-
mation). This study was not aimed at identifying novel 
markers for progression from CSA to RA, it aimed to 
explore the level of functional disability in patients 
with CSA and during progression to clinical arthritis. 
The question if a HAQ score is valuable for diagnostic 
or prognostic purposes needs to be studied in further, 
larger studies. Furthermore, future studies can explore 
if specific functional limitations are most predictive. 
Previous qualitative studies have shown the breadth of 
symptoms present in the early phase of RA21; further 
explorations on measures for recognising symptom 
patterns that are specific for pre-RA that include func-
tional limitations are warranted.
The severity of functional disability was associated with 
the severity of MRI-detected subclinical inflammation, 
indicating that the functional impairments were in part 
related to (subclinical) inflammation. Previous studies 
in early arthritis or in RA also showed an association 
between MRI-detected inflammation and HAQ scores 
within RA.11 22 In one of these studies, it was observed that 
MRI-detected tenosynovitis had the strongest association 
with functional disability in early arthritis.15 Interestingly, 
also in patients with CSA we observed that tenosynovitis 
had the strongest association with functional disability. 
The beta of MRI-detected tenosynovitis of 0.046 indi-
cates that a MRI-inflammation score of 6 associated with 
an increase in HAQ of 0.27. Although statistically signif-
icant, the relatively small effect size indicates that the 
functional disability in CSA is only partly explained by 
(MRI-detected) subclinical inflammation.
A potential weakness is that 37 patients did not 
complete the baseline HAQ. Because the baseline char-
acteristics of the patients who had HAQ data and those 
without HAQ data were similar, we believe that there is 
no important bias.
A previous study explored the impact of symptoms on 
daily functioning within antibody-positive patients with 
arthralgia.23 Our sets of patients is slightly different as 
autoantibody negative patients at risk for RA were also 
included and because patients were not included if the 
treating rheumatologist considered another explanation 
for the arthralgia (eg, osteoarthritis or fibromyalgia) 
more likely than imminent RA. In addition, anal-
yses were also repeated in the patients with arthralgia 
fulfilling the EULAR definition of arthralgia at risk for 
RA. These showed similar results. Importantly, as patients 
who had other explanations for the arthralgia were not 
included, we think it is unlikely that patients with forms 
of (chronic) pain syndromes might have skewed the data 
towards higher HAQ scores. Comparisons were based on 
medians of HAQ and VAS scores as these are more resis-
tant against outliers.
Another potential limitation for the analyses is that both 
HAQ scores and MRI-inflammation scores are assessed at 
semi-quantitative scales. However, the HAQ is one of the 
most important and validated patient-reported outcomes 
in RA.12
Finally, it should be taken into consideration that the 
sample size of patients converting to clinical arthritis is rela-
tively small. Our study is nevertheless the largest to date to 
investigate functional disability in patients with CSA.
Ideally, to fully evaluate the burden of clinically suspect 
arthralgia on functional disability, the functional status 
of the patients with CSA included in this study should be 
compared with age-matched and sex-matched controls 
from the general population. As such references were 
not available for the Dutch population, we could not 
perform such comparison.
In conclusion, functional disabilities exist already in the 
symptomatic prearthritis phase, with (on group level) a 
similar severity as when presenting with clinical arthritis. 
The occurrence of clinically detectable arthritis is a major 
event from the rheumatologist’s perspective as all trials 
in RA are performed in patients with clinically apparent 
arthritis. Hence, as soon as arthritis is clinically evident 
initiation of DMARD therapy may be warranted. Currently, 
several trials are being performed to investigate if treatment 
initiation in the phase of arthralgia is effective. As long as 
these trials have not reported positive results, there is no 
scientific evidence to start DMARD therapy in patients 
without clinical arthritis. Nonetheless, the present data 
illustrate that, from the patients’ perspective, the burden 
of disease is already severe in pre-RA. Acknowledging the 
importance of the symptomatic prearthritis phase from a 
functional perspective underlines the necessity of further 
studies to better identify patients with RA in the phase of 
arthralgia, and to verify the concept of very early treatment 
in these patients.
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